Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01016054 | A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | terminated | Phase 1 | 4 | Astellas Pharma IncINDUSTRY | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01177501 | Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma(ITOV04) | terminated | Phase 1 | 3 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 19, 2012 |
| clinicaltrials |
| NCT00005612 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer(ETC) | terminated | Phase 1 / Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT01212887 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | terminated | Phase 1 | 14 | Cancer Research UKOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT00317434 | Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer | terminated | Phase 1 | 12 | University of Alabama at BirminghamOTHER | 1 | Dec 15, 2009 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Feb 27, 2013source: clinicaltrials